Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Shandong Second Medical University | China

Author Profile

Scopus

🌟 Dr. Lv Huaiqing, M.D.

Chief Physician & Master’s Degree Supervisor

Director of Otorhinolaryngology & Head and Neck Surgery

Linyi People’s Hospital, Shandong Province

👩‍⚕️ Professional Summary:

Dr. Lv Huaiqing is a distinguished Chief Physician and subject leader at Linyi People’s Hospital, specializing in Otorhinolaryngology and Head and Neck Surgery. With extensive experience in clinical practice and research, Dr. Lv has significantly contributed to the field through her leadership roles and numerous scientific projects.

**🌐 Part-Time Roles:

  • Vice Chairman, Otorhinolaryngology, Head and Neck Surgery Committee, Shandong Provincial Medical Association
  • Vice Chairman, Hearing and Balance Medical Association, Shandong Provincial Medical Association
  • Member, Voice Committee, Otorhinolaryngology Committee, Chinese Association of Integrative Medicine
  • Standing Member, Head and Neck Tumor Committee, China Medical Education Association
  • Vice Chairman, Ear, Nose and Throat Committee, Shandong Association of Integrative Medicine
  • Vice Chairman, Pharyngeal, Head and Neck Surgery Committee, Shandong Provincial Association of Health Management
  • Director, Linyi Otorhinolaryngology Quality Control Center
  • Linyi Health Leader
  • Director, Otolaryngology Branch, Linyi Physicians Association

📚 Research Contributions:

Dr. Lv has authored 13 papers as the first author or corresponding author in the past year. She has presided over 3 provincial and municipal level projects, including:

  • Application of Posterior Auricular Groove Incision in Surgery of Benign Tumor of Parotid Gland
  • Evaluation of Orbital Invasion of Sinus Tumor Based on CT, MRI, and Machine Learning Models
  • Posterior Auricular Groove Incision in Surgery of Benign Tumor of Superficial Parotid Gland

Her research has received significant funding of 400,000 RMB and has led to several municipal science and technology awards. The research team excels in various methods, including bioinformatics, meta-analysis, and machine learning predictive models.

🎓 Teaching Commitment:

Currently, Dr. Lv supervises Master’s degree students at Qingdao University, Shandong Second Medical University, and Binzhou Medical College, having guided 10 students to date.

🔬 Current Publications:

She is also the first author or corresponding author of approximately 20 newly accepted and submitted articles in Chinese core or SCI journals.

Dr. Lv Huaiqing’s dedication to otorhinolaryngology, combined with her commitment to research and education, makes her a leading figure in her field.

🔔 Conclusion

Dr. Lv Huaiqing stands out as a prominent leader in Otorhinolaryngology and Head and Neck Surgery, with a rich background in clinical practice, research, and education. Her extensive involvement in various medical associations and committees demonstrates her commitment to advancing the field and enhancing patient care. Through her innovative research projects and dedication to mentoring future healthcare professionals, Dr. Lv continues to make significant contributions to medical science and the development of her specialty in Shandong Province and beyond.

📊🔬NOTABLE PUBLICATION:

    • Circ_0058124 upregulates MAPK1 expression to promote proliferation, metastasis and metabolic abilities in thyroid cancer through sponging miR-940
      • Authors: Sun, D., Chen, L., Lv, H., Liu, X., Zhang, X.
      • Journal: OncoTargets and Therapy
      • Year: 2020

     

    • Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway
      • Authors: Chen, Q., Wang, D., Chen, Z., Li, P., Lv, H.
      • Journal: Heliyon
      • Year: 2024

     

    • Genetically predicted allergic rhinitis causally increases the risk of erectile dysfunction
      • Authors: Li, P., Meng, Z., Lin, L., Chen, Z., Lv, H.
      • Journal: Frontiers in Genetics
      • Year: 2024

     

    • A novel frameshift mutation of the endoglin (ENG) gene causes hereditary hemorrhagic telangiectasia in a Chinese family
      • Authors: Li, P., Gao, C., Wei, Y., Shao, Q., Lv, H.
      • Journal: European Archives of Oto-Rhino-Laryngology
      • Year: 2024

     

    • Upregulation of microRNA-141 suppresses epithelial-mesenchymal transition and lymph node metastasis in laryngeal cancer through HOXC6-dependent TGF-β signaling pathway
      • Authors: Chen, L., Sun, D.-Z., Fu, Y.-G., Gao, Y., Zhang, X.-Y.
      • Journal: Cellular Signalling
      • Year: 2020

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Union Hospital, Tongii Medical | China

Author Profile

Scopus

Orcid id

🏥 Dr. Jianjun Xu: Pioneering Hepatobiliary Oncology Specialist

👨‍⚕️ Full Name: Jianjun Xu

🏅 Designation: Attending Doctor

🏨 Department:

  • Department of Hepatobiliary Surgery
  • Center for Liver Transplantation

🎓 Qualification: Doctor

🔬 Area of Specialization: Hepatobiliary Oncology and Cancer

💡 Sub Division: Oncology Therapeutics and Novel Approaches

🕒 Total Experience:

  • Work for 2 years
  • Doctor for 3 years
  • Master for 3 years
  • Bachelor for 5 years

 


🎓 Education

📚 2011-2016: Bachelor of Clinical Medicine, School of Medicine, Nanchang University.

🎓 2016-2019: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏫 2019-2022: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.


🏥 Experience

🩺 July 2022 to Present: Attending Doctor at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, China.


🔬 Contributions to Research, Innovations, and Extension Activities On Hepatobiliary Oncology and Cancer

Throughout his tenure, Dr. Jianjun Xu has made significant contributions to Tumor Research & Development, Innovations, and Extension Activities. Actively participating in research projects, he has advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. Leveraging his expertise in hepatobiliary malignancies, Dr. Xu collaborates with interdisciplinary teams to identify novel biomarkers, therapeutic targets, and treatment modalities, aiming to improve patient outcomes and quality of life.

Dr. Xu has also been involved in innovative initiatives to translate research findings into clinical practice. By fostering partnerships with industry stakeholders, academic institutions, and healthcare providers, he has facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

In addition to his research endeavors, Dr. Xu actively engages in extension activities to disseminate knowledge and promote awareness of cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the necessary information and resources to combat cancer effectively. His dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

NOTABLE PUBLICATION: